- Stocks
- Pharma & Healthcare
- GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals share price
NSE: GLAXOPharma & HealthcareDrug Manufacturers - General
GlaxoSmithKline Pharmaceuticals at a glance
GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) closed at ₹2,455.20 on 22 Oct 2026, up 0.17% on the day. With a market capitalisation of ₹41,228 Cr, it ranks 218th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 40.1× trailing earnings, against a return on equity of 47.7% in FY25. Over the past year the share price has fallen 9.1%. Its 52-week range is ₹2,088.10 (12 Jun 2026) to ₹3,120.70 (28 Aug 2026); the last close is 21.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹938 Cr (+16.6% year on year) and net profit ₹237 Cr (+15.7%), on a consolidated basis. Promoters held 75.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹41,228 CrRank 218 on NSE
- P/E (trailing)
- 40.1×
- Price to book
- 24.98×FY25
- EPS (TTM)
- ₹62.14to Q1 FY27
- ROE
- 47.7%FY25
- ROCE
- 57.0%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 24.7%FY25
- Book value / share
- ₹115.19FY25
- Dividend payout
- 80.1%FY25
- 52-week high
- ₹3,120.7028 Aug 2026
- 52-week low
- ₹2,088.1012 Jun 2026
- 1-year return
- −9.1%
- RSI (14-day)
- 28.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.17% | −3.3% | −14.5% | −3.9% | −9.1% |
GlaxoSmithKline Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,011 Cr | ₹949 Cr | ₹974 Cr | ₹805 Cr | ₹980 Cr | ₹1,041 Cr | ₹995 Cr | ₹938 Cr |
| Revenue YoY | +5.6% | +17.9% | +4.8% | −1.2% | −3.1% | +9.7% | +2.1% | +16.6% |
| Net profit | ₹253 Cr | ₹230 Cr | ₹263 Cr | ₹205 Cr | ₹257 Cr | ₹296 Cr | ₹278 Cr | ₹237 Cr |
| Net profit YoY | +16.1% | +402.8% | +35.2% | +12.4% | +2.0% | +28.6% | +5.7% | +15.7% |
| Net margin | 25.0% | 24.2% | 27.0% | 25.5% | 26.3% | 28.4% | 27.9% | 25.3% |
| EPS | ₹14.91 | ₹13.57 | ₹15.52 | ₹12.10 | ₹15.20 | ₹16.54 | ₹16.40 | ₹14.00 |
GlaxoSmithKline Pharmaceuticals financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,224 Cr | ₹2,926 Cr | ₹3,278 Cr | ₹3,252 Cr | ₹3,454 Cr | ₹3,749 Cr |
| Operating profit | ₹647 Cr | ₹627 Cr | ₹767 Cr | ₹837 Cr | ₹960 Cr | ₹1,255 Cr |
| Net profit | ₹93 Cr | ₹358 Cr | ₹1,695 Cr | ₹611 Cr | ₹590 Cr | ₹928 Cr |
| EPS (₹) | ₹6.00 | ₹31.00 | ₹99.00 | ₹36.00 | ₹41.00 | ₹55.00 |
| Cash from operations | ₹491 Cr | ₹578 Cr | ₹811 Cr | ₹484 Cr | ₹582 Cr | ₹1,290 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,821 Cr | ₹1,478 Cr | ₹2,663 Cr | ₹1,741 Cr | ₹1,778 Cr | ₹1,951 Cr |
GlaxoSmithKline Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions | 4.52% | 4.89% | 4.80% | 4.64% | 4.62% | 4.79% |
| Domestic institutions | 7.79% | 7.70% | 7.75% | 7.70% | 7.68% | 7.80% |
| Non-institutions | 12.69% | 12.41% | 12.45% | 12.66% | 12.69% | 12.41% |
GlaxoSmithKline Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to GlaxoSmithKline Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹48,293 Cr | 43 | 14.2% |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹47,020 Cr | 46.7 | 9.9% |
| ANTHEMAnthem Biosciences | ₹802.40 | −0.52% | +3.0% | ₹45,113 Cr | 76.6 | 19.4% |
| GLAXOGlaxoSmithKline Pharmaceuticals | ₹2,455.20 | +0.17% | −9.1% | ₹41,228 Cr | 40.1 | 47.7% |
| AJANTPHARMAjanta Pharma | ₹3,260.00 | 0.00% | +36.1% | ₹40,861 Cr | 38.6 | 23.3% |
| NHNarayana Hrudayalaya | ₹1,691.90 | −2.21% | −2.8% | ₹34,602 Cr | 42.4 | 17.8% |
| EMCUREEmcure Pharmaceuticals | ₹1,759.20 | +0.09% | +31.6% | ₹33,812 Cr | 145.1 | 18.7% |
Ask anything about GlaxoSmithKline Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against GLAXO's own history. Try: “Why has GLAXO moved over the last three months?” · “Backtest a 50-day moving-average crossover on GLAXO over five years” · “Compare GLAXO with IPCALAB on margins and valuation”
Frequently asked questions about GlaxoSmithKline Pharmaceuticals
What is the share price of GlaxoSmithKline Pharmaceuticals today?
GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) last closed at ₹2,455.20 on 22 Oct 2026. Its 52-week high is ₹3,120.70 and its 52-week low is ₹2,088.10.
What is the market cap of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals' market capitalisation is ₹41,228 Cr (₹41,228 Cr) at the 22 Oct 2026 close, ranking 218th among the NSE companies Pivot tracks.
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals trades at a trailing P/E of 40.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of GlaxoSmithKline Pharmaceuticals?
Return on equity was 47.7% in FY25 and return on capital employed was 57.0% in FY25 (consolidated figures).
Is GlaxoSmithKline Pharmaceuticals a debt-free company?
GlaxoSmithKline Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were GlaxoSmithKline Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), GlaxoSmithKline Pharmaceuticals reported revenue of ₹938 Cr, +16.6% year on year, and net profit of ₹237 Cr, +15.7% year on year.
How has GlaxoSmithKline Pharmaceuticals stock performed over the last year?
GlaxoSmithKline Pharmaceuticals' share price has fallen 9.1% over the past year, −3.9% over three months and −14.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of GlaxoSmithKline Pharmaceuticals?
As of 30 Jun 2026: promoters 75.00%, foreign institutions 4.79%, domestic institutions 7.80%, non-institutions 12.41%.
Who are GlaxoSmithKline Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to GlaxoSmithKline Pharmaceuticals by market cap are IPCA Laboratories, Gland Pharma, Anthem Biosciences, Ajanta Pharma, Narayana Hrudayalaya and Emcure Pharmaceuticals.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out GlaxoSmithKline Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLAXO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text